Author profile

Catherine (Caffi) Meyer, PhD, MS

Department of Nuclear Medicine and Theranostics, UCLA

AuthorsPoster
Voxel-Wise Dose Heterogeneity Following Yttrium-90 Glass Microsphere Radioembolization In HCC: Association with Pretreatment Tc-99m Maa SPECT/CT Tumor-to-Normal Ratio

Tumor-to-normal ratio (TNR) derived from pretreatment Tc-99m MAA SPECT/CT is widely used as a surrogate marker of perfusion in yttrium-90 (⁹⁰Y) radioembolization for patients with hepatocellular carcinoma (HCC). Delivered activity is critical for achieving ab...

Poster Program · Radiopharmaceuticals, Theranostics, and Nuclear Medicine
AuthorsPaper
Gastrointestinal Dosimetry of 177lu-PSMA-617 Radiopharmaceutical Therapy In Metastatic Prostate Cancer Patients: Results from a Single-Center Retrospective Study

Gastrointestinal (GI) adverse events following 177Lu-PSMA radiopharmaceutical therapy (RPT) occur frequently, including nausea, vomiting, constipation, and diarrhea (occurring in 19-35% of patients). Despite the frequent occurrence of GI-related toxicities, t...

Proffered Program · Radiopharmaceuticals, Theranostics, and Nuclear Medicine